Following post-graduate training as an internist, rheumatologist and immunologist at Tufts New England Medical Center, Harvard's Robert B. Brigham Hospital and the National Cancer Institute, N.I.H. in Bethesda, MD, Bruce joined the faculty at the Medical College of Virginia, Virginia Commonwealth University. During 13 years at M.C.V. his laboratory research was on cytokine regulation of complement production and the mode of action of RA DMARDs. His translational and clinical research interests were rheumatoid arthritis pathogenesis and treatment.
After joining Pfizer's first Experimental Medicine group in 1989, Bruce's main focus became translational pharmacology, biomarker driven development decisions and exploratory clinical development across multiple therapeutic areas. He became the head of the Experimental Medicine group at legacy Pfizer and later was instrumental in starting Pfizer's Clinical Pharmacogenomics group and Pfizer's first biomarker laboratory. He played a key role in implementing important organizational changes through two major acquisitions.
As Vice President, Global Head of Translational Medicine, he established Pfizer's Global Translational Medicine organization with groups in each of eleven therapeutic areas. Translational Medicine worked to improve Phase 2 survival through biomarker development for early validation of drug targets; demonstration of desired pharmacological activity in Phase 1; and development of clinical methods and biomarkers to advance the development of Pfizer products. In addition Bruce had other global responsibilities as a member of the Clinical Quantitative and Innovative Medicine Leadership Team, Scientific Excellence Board and CAN Quality Guidelines Committee. Bruce is also Co-Chair of the Inflammation and Immunity Steering Committee of The Biomarker Consortium (Foundation for the NIH) and Co-Chair of the Predictive Efficacy Models Working Group, a PISC PhRMA initiative.
After 19 years at Pfizer, in December 2007 Bruce retired and started an independent consulting company, Translational Medicine Associates, LLC (TMA). Bruce also remains co-chair for the Inflammation and Immunity Steering Committee of The Biomarker Consortium (Foundation for the NIH).
Through TMA, Bruce serves customers in the areas of translational research, early clinical development planning and execution, risk assessment for early biotech and drug investment opportunities and biomarker development. In addition TMA helps guide biotech and translational research companies through Bruce's membership on boards of directors. TMA is also able to network with many experts in these and related areas of translational research, biomarker development, pharmaceutical sciences and clinicians in multiple therapeutic areas.